The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ATXI | -64.84% | -99.98% | -82.09% | -100% |
| S&P | +16.9% | +95.99% | +14.39% | +181% |
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.40M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $0.64M | -80.6% |
| Market Cap / Employee | $0.32M | 0.0% |
| Employees | 2 | -33.3% |
| Net Income | $0.33M | 104.6% |
| EBITDA | $0.30M | 110.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.33M | -32.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -134.16% | 177.2% |
| Return On Invested Capital | -297.99% | -7.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.18M | 92.2% |
| Operating Free Cash Flow | -$0.18M | 92.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.62 | 1.23 | 0.23 | 0.18 | -75.01% |
| Price to Sales | 0.46 | - | |||
| Price to Tangible Book Value | 0.62 | 1.23 | 0.23 | 0.18 | -75.01% |
| Enterprise Value to EBITDA | -0.14 | -0.43 | 1.99 | -13.18 | -2013.46% |
| Return on Equity | -1037.7% | -737.4% | -430.4% | -139.1% | -63.22% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
